DOCSLIB.ORG

Mathematics Course: Algebra I Honors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mathematics Course: Algebra I Honors Mathematics Course: Algebra I Honors Overview: This course is a study of the algebraic language and concepts, together with the skills needed to master these concepts. Students will study the basics of arithmetic, real numbers, equations, inequalities, linear graphs and equations, systems of equations, rational exponents, polynomials, factoring, rational expressions and equations, radicals, quadratic equations and graphs. Algebra, Mathematical Models, and Problem Solving Alg1.1 Algebraic Expressions, Real Numbers, and Interval Notation Alg1.1a Translate English phrases into algebraic expressions Alg1.1b Evaluate algebraic expressions Alg1.1c Use mathematical models Alg1.1d Recognize the sets that make up the real numbers Alg 1.1e Use set‐builder notation Alg 1.1f Use the symbols “element of” and is “not an element of” Alg 1.1g Use inequality notation Alg 1.1h Use Interval notation Alg1.2 Operations with Real Numbers and Simplifying Algebraic Expressions Alg1.2a Find a number's absolute value Alg1.2b Add real numbers Alg1.2c Find opposites Alg 1.2d Subtract real numbers Alg1.2e Multiply real numbers Alg1.2f Evaluate exponential expressions Alg1.2g Divide real numbers Alg1.2h Use order of operations Alg1.2i Use commutative, associative, and distributive properties Alg1.2j Simplify algebraic expressions Alg1.3 Graphing equations Alg1.3a Plot points in the rectangular coordinate system Alg1.3b Graph equations in the rectangular coordinate system Alg1.3c Use the rectangular coordinate system to visualize relationships between variables. Alg1.3d Interpret information about a graphing utility’s viewing rectangle or table. Alg1.4 Solving Linear Equations Alg1.4a Solve linear equations Alg1.4b recognize identities, conditional equations, and inconsistent equations Alg1.4c Solve applied problems using mathematical models Alg1.5 Problem solving and Using Formulas Alg1.5a Solve algebraic word problems using linear equations Alg1.5b Solve a formula for a variable Alg1.6 Properties of Integral Exponents Alg1.6a Use the product rule Alg1.6b Use the quotient rule Alg1.6c Use the zero‐exponent rule Alg1.6d Use the negative‐exponent rule Alg1.6e Use the power rule Alg1.6f Find the power of a product Alg1.6g Find the power of a quotient Alg1.6h Simplify exponential expressions Alg1.7 Scientific Notation Alg1.7a Convert from scientific to decimal notation Alg1.7b Convert from decimal to scientific notation Alg1.7c Perform computations with scientific notation Alg1.7d Use scientific notation to solve problems Functions and Linear Functions Alg2.1 Introductions to Functions Alg2.1a Find the domain and range of a relation Alg2.1b Determine whether a relation is a function Alg2.1c Evaluate a function Alg2.2 Graphs of Functions Alg2.2a Graph functions by plotting points Alg2.2b Use the vertical line test to identify functions Alg2.2c Obtain information about a function from its graph Alg2.2d Identify the domain and range of a function from its graph Alg2.3 The Algebra of Functions Alg2.3a Find the domain of a function Alg2.3b Use the algebra of functions to combine functions and determine domains. Alg2.4 Linear Functions and Slope Alg2.4a Use intercepts to graph a linear function in standard form Alg2.4b Compute a line’s slope Alg2.4c Find a line’s slope and y‐intercept from its equation Alg2.4d Graph linear functions in slope‐intercept form Alg2.4d Graph horizontal or vertical lines Alg2.4e Interpret slope as rate of change Alg2.4f Find a function’s average rate of change Alg2.4g Use slope and y‐intercept to model data Alg2.5 The point‐slope from of the equation Alg2.5a Use the point‐slope form to write equations of a line Alg2.5b Model data with linear functions and make predictions Alg2.5c Find slopes and equations of parallel and perpendicular lines Systems of Linear Equations Alg3.1 Systems of Linear Equations in Two Variables. Alg3.1a Read bar and line graphs Alg3.1b Determine whether an ordered pair is a solution Alg3.1c Solve by graphing, substitution and addition Alg3.1d Select most efficient method Alg3.1e Identify systems with other solutions other than one ordered pair Alg3.2 Problem Solving and Business Applications using Systems of Equations Alg3.2a Solve problems using systems Alg3.2b Using functions to model revenue, cost and profit and break‐even point Alg3.2c Solve problems using systems of equations Alg3.3 Systems of Linear Equations in Three Variables Alg3.3a Verify the solution Alg3.3b Solve systems of equations in 3 variables Alg3.3c Identify inconsistent and dependent systems Alg3.3d Solve problems using a system in 3 variables Alg3.4 Matrix Solutions to Linear Systems Alg3.4a Write the augmented matrix Alg3.4b Perform matrix row operations Alg3.4c Use matrices to solve linear systems in 2 variables Alg3.4d Use matrices to solve linear systems in 3 variables Alg3.4e Use matrices to identify inconsistent and dependent systems Alg3.5 Determinants and Cramer's Rule Alg3.5a Evaluate a second order determinant Alg3.5b Solve a system of 2 variables using Cramer's rule Alg3.5c Evaluate a third order determinant Alg3.5d Solve a system in 3 variables using Cramer's rule Inequalities and Problem Solving Alg4.1 Solving Linear Inequalities Alg4.1a Solve linear inequalities Alg4.1b Recognize inequalities with no solution or all real numbers as solutions Alg4.1c Solve applied problems using linear inequalities Alg4.2 Compound Inequalities Alg4.2a Find the intersection of two sets and the union of two sets Alg4.2b Solve compound inequalities containing And, Or Alg4.3 Absolute Value Equations and Inequalities Alg4.3a Solve absolute value equations Alg4.3b Solve absolute value inequalities in the form lxl <a Alg4.3c Solve absolute value inequalities in the form lxl>a Alg4.4d Recognize absolute value inequalities with no solution or all real numbers Alg4.5e Solve problems using absolute value inequalities Alg4.4 Linear Inequalities in Two Variables Alg4.4a Graph a linear inequality in two variables Alg4.4b Graph a system of inequalities Alg4.5 Linear Programming Alg4.5a Write objective functions Alg4.5b Use inequalities to model the limitations Alg4.5c Use linear programming to solve problems Polynomials, Polynomial Functions, and Factoring Systems of Linear Equations and Inequalities Alg5.1 Introduction to Polynomials and Polynomial Functions Alg5.1a Use vocabulary of polynomials Alg5.1b Evaluate polynomial functions Alg5.1c Determine end behavior Alg5.1d Add and subtract polynomials Alg5.2 Multiplication of Polynomials Alg5.2a Multiply monomials, monomials to polynomials Alg5.2b Multiply all forms of polynomials Alg5.2c Use FOIL Alg5.2d Square binomial, multiply sum and difference Alg5.2e Find the product of functions Alg5.2f Use polynomial functions to evaluate functions Alg5.3 Greatest Common Factors and Factoring by Grouping Alg5.3a Factor out the GCF of a polynomial Alg5.3b Factor out a common factor and a negative coefficient Alg5.3c Factor by grouping Alg5.4 Factoring Trinomials Alg5.4a Factor a trinomial with leading coefficient is 1 Alg5.4b Factor using substitution Alg5.4c Factor a trinomial with leading coefficient other than 1 Algd5.4d Factor trinomials by grouping Alg5.5 Factoring Special Forms Alg5.5a Factor the difference of two square Alg5.5b Factor perfect square trinomials Alg5.5c Use grouping to obtain the difference of two squares Alg5.5d Factor the sum or difference of two cubes Alg5.6 A General Factoring Strategy Alg5.6a Use a general factoring strategy for polynomials Alg5.7 Polynomial Equations and Their Applications Alg5.7a Solve quadratic equations by factoring Alg5.7b Solve higher degree polynomial equations by factoring Alg5.7c Solve problems using polynomial equations Rational Expressions, Functions, and Equations and Polynomials Alg6.1 Multiplying and Dividing Rational Expressions and Functions Alg6.1a Evaluate rational functions Alg6.1b Find the domain of a rational function Alg6.1c Interpret the information given by the graph of a rational function Alg6.1d Simplify rational expressions Alg6.1e Multiply and Divide rational expressions Alg6.2 Adding and Subtracting Rational Expressions Alg6.2a Add and Subtract expressions with the same denominator Alg6.2b Find the LCD Alg6.2c Add and Subtract expressions with different denominators Alg6.3 Complex Rational Expressions Alg6.3a Simplify complex rational expressions by multiplying by 1 Alg6.3b Simplify complex rational expressions by dividing Alg6.4 Dividing Polynomials Alg6.4a Divide a polynomial by a monomial Alg6.4b Use long division to divide a polynomial by another polynomial Alg6.5 Synthetic Division and the Remainder Theorem Alg6.5a Divide using synthetic division Alg6.5b Evaluate a polynomial function using the Remainder Theorem Alg6.5c Show a number is a solution using the Remainder Theorem Alg6.6 Rational Equations Alg6.5a Solve rational equations Alg6.5b Solve problems involving rational functions that model applied situations Alg6.7 Formulas and Applications of Rational Equations Alg6.7a Solve a formula with a rational expression for a variable Alg6.7b Solve business problems involving average cost Alg6.7c Solve problems involving time in motion Alg6.7d Solve problems involving work Alg6.8 Modeling Using Variation Alg6.8a Solve direct variation Alg6.8b Solve inverse variation Alg6.8c Solve combined variation Alg6.8d Solve joint variation Radicals, Radical Functions, and Rational Exponents and Polynomials Alg7.1 Radical Expressions and Functions Alg7.1a Evaluate square roots and functions Alg7.1b Find the domain of the square root function Alg7.1c Model
Load more

Recommended publications
  • The Diversity of Dolichol-Linked Precursors to Asn-Linked Glycans Likely Results from Secondary Loss of Sets of Glycosyltransferases
    The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets of glycosyltransferases John Samuelson*†, Sulagna Banerjee*, Paula Magnelli*, Jike Cui*, Daniel J. Kelleher‡, Reid Gilmore‡, and Phillips W. Robbins* *Department of Molecular and Cell Biology, Boston University Goldman School of Dental Medicine, 715 Albany Street, Boston, MA 02118-2932; and ‡Department of Biochemistry and Molecular Biology, University of Massachusetts Medical School, Worcester, MA 01665-0103 Contributed by Phillips W. Robbins, December 17, 2004 The vast majority of eukaryotes (fungi, plants, animals, slime mold, to N-glycans of improperly folded proteins, which are retained in and euglena) synthesize Asn-linked glycans (Alg) by means of a the ER by conserved glucose-binding lectins (calnexin͞calreticulin) lipid-linked precursor dolichol-PP-GlcNAc2Man9Glc3. Knowledge of (13). Although the Alg glycosyltransferases in the lumen of ER this pathway is important because defects in the glycosyltrans- appear to be eukaryote-specific, archaea and Campylobacter sp. ferases (Alg1–Alg12 and others not yet identified), which make glycosylate the sequon Asn and͞or contain glycosyltransferases dolichol-PP-glycans, lead to numerous congenital disorders of with domains like those of Alg1, Alg2, Alg7, and STT3 (1, 14–16). glycosylation. Here we used bioinformatic and experimental Protists, unicellular eukaryotes, suggest three notable exceptions methods to characterize Alg glycosyltransferases and dolichol- to the N-linked glycosylation path described in yeast and animals PP-glycans of diverse protists, including many human patho- (17). First, the kinetoplastid Trypanosoma cruzi (cause of Chagas gens, with the following major conclusions. First, it is demon- myocarditis), fails to glucosylate the dolichol-PP-linked precursor strated that common ancestry is a useful method of predicting and so makes dolichol-PP-GlcNAc2Man9 (18).
    [Show full text]
  • Physical Interactions Between the Alg1, Alg2, and Alg11 Mannosyltransferases of the Endoplasmic Reticulum
    Glycobiology vol. 14 no. 6 pp. 559±570, 2004 DOI: 10.1093/glycob/cwh072 Advance Access publication on March 24, 2004 Physical interactions between the Alg1, Alg2, and Alg11 mannosyltransferases of the endoplasmic reticulum Xiao-Dong Gao2, Akiko Nishikawa1, and Neta Dean1 begins on the cytosolic face of the ER, where seven sugars (two N-acetylglucoseamines and five mannoses) are added 1Department of Biochemistry and Cell Biology, Institute for Cell and Developmental Biology, State University of New York, Stony Brook, sequentially to dolichyl phosphate on the outer leaflet of NY 11794-5215, and 2Research Center for Glycoscience, National the ER, using nucleotide sugar donors (Abeijon and Institute of Advanced Industrial Science and Technology, Tsukuba Hirschberg, 1992; Perez and Hirschberg, 1986; Snider and Downloaded from https://academic.oup.com/glycob/article/14/6/559/638968 by guest on 30 September 2021 Central 6, 1-1 Higashi, Tsukuba 305-8566, Japan Rogers, 1984). After a ``flipping'' or translocation step, the Received on January 26, 2004; revised on March 2, 2004; accepted on last seven sugars (four mannoses and three glucoses) are March 2, 2004 added within the lumen of the ER, using dolichol-linked sugar donors (Burda and Aebi, 1999). Once assembled, the The early steps of N-linked glycosylation involve the synthesis oligosaccharide is transferred from the lipid to nascent of a lipid-linked oligosaccharide, Glc3Man9GlcNAc2-PP- protein in a reaction catalyzed by oligosaccharyltransferase. dolichol, on the endoplasmic reticulum (ER) membrane. After removal of terminal glucoses and a single mannose, Prior to its lumenal translocation and transfer to nascent nascent glycoproteins bearing the N-linked Man8GlcNAc2 glycoproteins, mannosylation of Man5GlcNAc2-PP-dolichol core can exit the ER to the Golgi, where this core may is catalyzed by the Alg1, Alg2, and Alg11 mannosyltrans- undergo further carbohydrate modifications.
    [Show full text]
  • Yeast Genome Gazetteer P35-65
    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
    [Show full text]
  • Congenital Disorders of Glycosylation from a Neurological Perspective
    brain sciences Review Congenital Disorders of Glycosylation from a Neurological Perspective Justyna Paprocka 1,* , Aleksandra Jezela-Stanek 2 , Anna Tylki-Szyma´nska 3 and Stephanie Grunewald 4 1 Department of Pediatric Neurology, Faculty of Medical Science in Katowice, Medical University of Silesia, 40-752 Katowice, Poland 2 Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland; [email protected] 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, W 04-730 Warsaw, Poland; [email protected] 4 NIHR Biomedical Research Center (BRC), Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, London SE1 9RT, UK; [email protected] * Correspondence: [email protected]; Tel.: +48-606-415-888 Abstract: Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post- translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations
    [Show full text]
  • We Consider the Ordinary Differential Equation Model of the Metal Rolling
    We consider the ordinary differential equation model of the metal rolling process defined in K. Gal- kowski, E. Rogers, W. Paszke and D. H. Owens, Linear repetitive process control theory applied to a physical example, Int. J. Appl. Comput. Sci., 13 (2003), 87-99. In order to do that, we firstly define the Ore algebra formed by the derivative D w.r.t. time t and by the shift operator S acting on the discrete variable k which denotes the pass number. > Alg1 := DefineOreAlgebra(diff=[D,t], dual_shift=[S,k], polynom=[t,k], > comm=[lambda,lambda1,lambda2,M]): The system matrix is defined by: > R1 := evalm([[D^2+lambda/M-(lambda/lambda1)*D^2*S-(lambda/M)*S, > lambda/(M*lambda2)]]); λ λ D2 S λ S λ R1 := D2 + − − M λ1 M M λ2 Then, the system is defined by the following equation > ApplyMatrix(R1, [y(t,k), FM(t,k)], Alg1)[1,1]=0; (λ y(t, k) λ1 λ2 − λ y(t, k − 1) λ1 λ2 + D1, 1(y)(t, k) M λ1 λ2 − λ D1, 1(y)(t, k − 1) M λ2 + λ FM(t, k) λ1)/(M λ1 λ2) = 0 which corresponds to (4) of the previously quoted paper. Let us check the structural properties of the previous system (e.g., controllability, parametrizability, flatness). > R1_adj := Involution(R1, Alg1): It is known that the Alg1 -module associated with the matrix R1 is torsion-free iff the first extension module of the Alg1 -module associated with R1 adj with values in Alg1 is 0. We compute this extension module by using Exti: > Ext1 := Exti(R1_adj, Alg1, 1); Ext1 := [ 1 , M λ D2 S λ2 − M D2 λ1 λ2 + λ S λ1 λ2 − λ λ1 λ2 −λ λ1 , −λ λ1 ] M D2 λ1 λ2 − M λ D2 S λ2 + λ λ1 λ2 − λ S λ1 λ2 As the first matrix Ext1 [1] is an identity matrix, we obtain that the Alg1 -module associated with R1 is torsion-free, and thus, the corresponding system is controllable and parametrizable.
    [Show full text]
  • Molecular Diagnostic Requisition
    BAYLOR MIRACA GENETICS LABORATORIES SHIP TO: Baylor Miraca Genetics Laboratories 2450 Holcombe, Grand Blvd. -Receiving Dock PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bmgl.com Houston, TX 77021-2024 Phone: 713-798-6555 MOLECULAR DIAGNOSTIC REQUISITION PATIENT INFORMATION SAMPLE INFORMATION NAME: DATE OF COLLECTION: / / LAST NAME FIRST NAME MI MM DD YY HOSPITAL#: ACCESSION#: DATE OF BIRTH: / / GENDER (Please select one): FEMALE MALE MM DD YY SAMPLE TYPE (Please select one): ETHNIC BACKGROUND (Select all that apply): UNKNOWN BLOOD AFRICAN AMERICAN CORD BLOOD ASIAN SKELETAL MUSCLE ASHKENAZIC JEWISH MUSCLE EUROPEAN CAUCASIAN -OR- DNA (Specify Source): HISPANIC NATIVE AMERICAN INDIAN PLACE PATIENT STICKER HERE OTHER JEWISH OTHER (Specify): OTHER (Please specify): REPORTING INFORMATION ADDITIONAL PROFESSIONAL REPORT RECIPIENTS PHYSICIAN: NAME: INSTITUTION: PHONE: FAX: PHONE: FAX: NAME: EMAIL (INTERNATIONAL CLIENT REQUIREMENT): PHONE: FAX: INDICATION FOR STUDY SYMPTOMATIC (Summarize below.): *FAMILIAL MUTATION/VARIANT ANALYSIS: COMPLETE ALL FIELDS BELOW AND ATTACH THE PROBAND'S REPORT. GENE NAME: ASYMPTOMATIC/POSITIVE FAMILY HISTORY: (ATTACH FAMILY HISTORY) MUTATION/UNCLASSIFIED VARIANT: RELATIONSHIP TO PROBAND: THIS INDIVIDUAL IS CURRENTLY: SYMPTOMATIC ASYMPTOMATIC *If family mutation is known, complete the FAMILIAL MUTATION/ VARIANT ANALYSIS section. NAME OF PROBAND: ASYMPTOMATIC/POPULATION SCREENING RELATIONSHIP TO PROBAND: OTHER (Specify clinical findings below): BMGL LAB#: A COPY OF ORIGINAL RESULTS ATTACHED IF PROBAND TESTING WAS PERFORMED AT ANOTHER LAB, CALL TO DISCUSS PRIOR TO SENDING SAMPLE. A POSITIVE CONTROL MAY BE REQUIRED IN SOME CASES. REQUIRED: NEW YORK STATE PHYSICIAN SIGNATURE OF CONSENT I certify that the patient specified above and/or their legal guardian has been informed of the benefits, risks, and limitations of the laboratory test(s) requested.
    [Show full text]
  • Associated with Low Dehydrodolichol Diphosphate Synthase (DHDDS) Activity S
    Sabry et al. Orphanet Journal of Rare Diseases (2016) 11:84 DOI 10.1186/s13023-016-0468-1 RESEARCH Open Access A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity S. Sabry1,2,3,4, S. Vuillaumier-Barrot1,2,5, E. Mintet1,2, M. Fasseu1,2, V. Valayannopoulos6, D. Héron7,8, N. Dorison8, C. Mignot7,8,9, N. Seta5,10, I. Chantret1,2, T. Dupré1,2,5 and S. E. H. Moore1,2* Abstract Background: Type I congenital disorders of glycosylation (CDG-I) are mostly complex multisystemic diseases associated with hypoglycosylated serum glycoproteins. A subgroup harbour mutations in genes necessary for the biosynthesis of the dolichol-linked oligosaccharide (DLO) precursor that is essential for protein N-glycosylation. Here, our objective was to identify the molecular origins of disease in such a CDG-Ix patient presenting with axial hypotonia, peripheral hypertonia, enlarged liver, micropenis, cryptorchidism and sensorineural deafness associated with hypo glycosylated serum glycoproteins. Results: Targeted sequencing of DNA revealed a splice site mutation in intron 5 and a non-sense mutation in exon 4 of the dehydrodolichol diphosphate synthase gene (DHDDS). Skin biopsy fibroblasts derived from the patient revealed ~20 % residual DHDDS mRNA, ~35 % residual DHDDS activity, reduced dolichol-phosphate, truncated DLO and N-glycans, and an increased ratio of [2-3H]mannose labeled glycoprotein to [2-3H]mannose labeled DLO. Predicted truncated DHDDS transcripts did not complement rer2-deficient yeast. SiRNA-mediated down-regulation of DHDDS in human hepatocellular carcinoma HepG2 cells largely mirrored the biochemical phenotype of cells from the patient.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Prenatal Testing Requisition Form
    BAYLOR MIRACA GENETICS LABORATORIES SHIP TO: Baylor Miraca Genetics Laboratories 2450 Holcombe, Grand Blvd. -Receiving Dock PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bmgl.com Houston, TX 77021-2024 Phone: 713-798-6555 PRENATAL COMPREHENSIVE REQUISITION FORM PATIENT INFORMATION NAME (LAST,FIRST, MI): DATE OF BIRTH (MM/DD/YY): HOSPITAL#: ACCESSION#: REPORTING INFORMATION ADDITIONAL PROFESSIONAL REPORT RECIPIENTS PHYSICIAN: NAME: INSTITUTION: PHONE: FAX: PHONE: FAX: NAME: EMAIL (INTERNATIONAL CLIENT REQUIREMENT): PHONE: FAX: SAMPLE INFORMATION CLINICAL INDICATION FETAL SPECIMEN TYPE Pregnancy at risk for specific genetic disorder DATE OF COLLECTION: (Complete FAMILIAL MUTATION information below) Amniotic Fluid: cc AMA PERFORMING PHYSICIAN: CVS: mg TA TC Abnormal Maternal Screen: Fetal Blood: cc GESTATIONAL AGE (GA) Calculation for AF-AFP* NTD TRI 21 TRI 18 Other: SELECT ONLY ONE: Abnormal NIPT (attach report): POC/Fetal Tissue, Type: TRI 21 TRI 13 TRI 18 Other: Cultured Amniocytes U/S DATE (MM/DD/YY): Abnormal U/S (SPECIFY): Cultured CVS GA ON U/S DATE: WKS DAYS PARENTAL BLOODS - REQUIRED FOR CMA -OR- Maternal Blood Date of Collection: Multiple Pregnancy Losses LMP DATE (MM/DD/YY): Parental Concern Paternal Blood Date of Collection: Other Indication (DETAIL AND ATTACH REPORT): *Important: U/S dating will be used if no selection is made. Name: Note: Results will differ depending on method checked. Last Name First Name U/S dating increases overall screening performance. Date of Birth: KNOWN FAMILIAL MUTATION/DISORDER SPECIFIC PRENATAL TESTING Notice: Prior to ordering testing for any of the disorders listed, you must call the lab and discuss the clinical history and sample requirements with a genetic counselor.
    [Show full text]
  • Myo-Glyco Disease Biology: Genetic Myopathies Caused by Abnormal Glycan Synthesis and Degradation
    Journal of Neuromuscular Diseases 6 (2019) 175–187 175 DOI 10.3233/JND-180369 IOS Press Review Myo-Glyco disease Biology: Genetic Myopathies Caused by Abnormal Glycan Synthesis and Degradation Motoi Kanagawa∗ Division of Molecular Brain Science, Kobe University Graduate School of Medicine, Japan Abstract. Glycosylation is a major form of post-translational modification and plays various important roles in organisms by modifying proteins or lipids, which generates functional variability and can increase their stability. Because of the physiological importance of glycosylation, defects in genes encoding proteins involved in glycosylation or glycan degradation are sometimes associated with human diseases. A number of genetic neuromuscular diseases are caused by abnormal glycan modification or degeneration. Heterogeneous and complex modification machinery, and difficulties in structural and functional analysis of glycans have impeded the understanding of how glycosylation contributes to pathology. However, recent rapid advances in glycan and genetic analyses, as well as accumulating genetic and clinical information have greatly contributed to identifying glycan structures and modification enzymes, which has led to breakthroughs in the understanding of the molecular pathogenesis of various diseases and the possible development of therapeutic strategies. For example, studies on the relationship between glycosylation and muscular dystrophy in the last two decades have significantly impacted the fields of glycobiology and neuromyology. In this review, the basis of glycan structure and biosynthesis will be briefly explained, and then molecular pathogenesis and therapeutic concepts related to neuromuscular diseases will be introduced from the point of view of the life cycle of a glycan molecule. Keywords: Glycosylation, muscular dystrophy, neuromuscular disease, therapeutic strategy STRUCTURE AND CELL BIOLOGY OF of a glycoconjugate, such as a glycoprotein and GLYCANS – AN OVERVIEW glycolipid.
    [Show full text]
  • Targeted Proteomics Reveals Quantitative Differences in Low Abundance Glycosyltransferases of Patients with Congenital Disorders of Glycosylation
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.15.291732; this version posted September 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Targeted Proteomics Reveals Quantitative Differences in Low Abundance Glycosyltransferases of Patients with Congenital Disorders of Glycosylation Roman Sakson1,2,*, Lars Beedgen3,*, Patrick Bernhard4,5,6, Keziban M. Alp7, Ni- cole Lübbehusen1, Ralph Röth8, Beate Niesler8,9, Matthias P. Mayer1, Christian Thiel3 and Thomas Ruppert1,# 1 Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Alliance, Heidelberg, Germany 2 HBIGS, Heidelberg Biosciences International Graduate School, Heidelberg Univer- sity, 69120 Heidelberg, Germany 3 Center for Child and Adolescent Medicine, Department Pediatrics I, Heidelberg Uni- versity, 69120 Heidelberg, Germany 4 Institute for Surgical Pathology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany 5 Spemann Graduate School of Biology and Medicine (SGBM), University of Frei- burg, Germany 6 Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany 7 Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 12135 Berlin, Germany 8 Department of Human Molecular Genetics, University Hospital Heidelberg, Heidel- berg, Germany 9 Interdisciplinary Center for Neurosciences, Heidelberg University, Heidelberg, Ger- many * equal contribution # corresponding author bioRxiv preprint doi: https://doi.org/10.1101/2020.09.15.291732; this version posted September 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Protein glycosylation is essential in all domains of life and its mutational impairment in humans can result in severe diseases named Congenital Disorders of Glycosylation (CDGs).
    [Show full text]
  • F04b57ca351b0dc3389ebe992c
    Review Insights into complexity of congenital disorders of glycosylation Sandra Supraha Goreta*, Sanja Dabelic, Jerka Dumic University of Zagreb, Faculty of Pharmacy and Biochemistry, Department of Biochemistry and Molecular Biology, Zagreb, Croatia *Corresponding author: [email protected] Abstract Biochemical and biological properties of glycoconjugates are strongly determined by the specifi c structure of its glycan parts. Glycosylation, the covalent attachment of sugars to proteins and lipids, is very complex and highly-coordinated process involving > 250 gene products. Defi ciency of glycosylation enzymes or transporters results in impaired glycosylation, and consequently pathological modulation of many physiological processes. Inborn defects of glycosylation enzymes, caused by the specifi cmutations, lead to the development of rare, but severe diseases – congenital disor- ders of glycosylation (CDGs). Up today, there are more than 45 known CDGs. Their clinical manifestations range from very mild to extremely severe (even lethal) and unfortunately, only three of them can be eff ectively treated nowadays. CDG symptoms highly vary, though someare common for several CDG types but also for other unrelated diseases, especially neurological ones, leaving the possibility that many CDGs cases are under- or mis- diagnosed. Glycan analysis of serum transferrin (by isoelectric focusing or more sophisticated methods, such as HPLC (high-performance liquid chro- matography) or MALDI (matrix-assisted laser desorption/ionization)) or serum N-glycans
    [Show full text]